Aeglea BioTherapeutics Inc logo

Aeglea BioTherapeutics Inc

$ 0.53 +0.002 (+0.38%) 04:00 PM EST
P/E:
At Loss
P/B:
0.40
Market Cap:
$ 32.42M
Enterprise V:
$ -51.46M
Volume:
124.45K
Avg Vol (2M):
2.91M
Volume:
124.45K
Market Cap $:
32.42M
PE Ratio:
At Loss
Avg Vol (2-Month):
2.91M
Enterprise Value $:
-51.46M
PB Ratio:
0.40
GF Score:
Year:
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
Aeglea BioTherapeutics Inc is a clinical-stage biotechnology company. It designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in an early clinical development stage.
Name Current Vs Industry Vs History
Cash-To-Debt 18.48
Equity-to-Asset 0.79
Debt-to-Equity 0.06
Debt-to-EBITDA -0.06
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 1/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -5.93
Distress
Grey
Safe
Beneish M-Score -3.37
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 62.9
9-Day RSI 56.9
14-Day RSI 53.2
6-1 Month Momentum % -79.77
12-1 Month Momentum % -93.6

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 6.09
Quick Ratio 6.09
Cash Ratio 5.58
Days Sales Outstanding 1116.29

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -26.9

Financials (Next Earnings Date:2022-11-04 Est.)

AGLE's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:AGLE

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Valuation Box

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 7.03
EPS (TTM) ($) -1.26
Beta 1.77
Volatility % 83.65
14-Day RSI 53.2
14-Day ATR ($) 0.051317
20-Day SMA ($) 0.49415
12-1 Month Momentum % -93.6
52-Week Range ($) 0.372 - 8.5
Shares Outstanding (Mil) 61.17

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 1
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Aeglea BioTherapeutics Inc Filings

Document Form Filing Date
No Filing Data

Aeglea BioTherapeutics Inc Analysis

Share your research

Headlines

See More
No news.